Therapeutics News

MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.

MIAMI BEACH, Fla. — Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according to a speaker at Masters of Pediatric Dermatology.

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse cutaneous systemic sclerosis, according to data published in Arthritis Care & Research.

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study.

The American Society for Dermatologic Surgery Association has called on legislators for medical spa regulation following the publication of its study which showed a continued lack of physician supervision.

Researchers found genetic differences in hereditary palmoplantar keratoderma subtypes, indicating that genetic testing may be a valuable tool in accurately diagnosing the disease, according to a study.

The dermatology space has seen many FDA approvals and expansions in 2024.

An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.